Factor XI inhibiTion for the Prevention of Venous Thromboembolism in Patients Undergoing Total Knee Arthroplasty

• Status: Recruiting
• Trial end date: 2026-04-15
• Target enrollment: 0
• Participant gender: All

Summary

This study was to compare the study drug KN060 to enoxaparin, for the prevention of blood clotting and safety in patients undergoing total knee arthroplasty (TKA).

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Suzhou Alphamab Co., Ltd.
• Treatments: Enoxaparin

Criteria

Inclusion Criteria:

1. Male or female, aged between 18 and 75 years old (including the cut-off value);

2. undergoing unilateral Total Knee Arthroplasty (TKA);

3. Voluntarily participate in the study and sign a written informed consent;

Exclusion Criteria:

1. There is a high risk of bleeding or abnormal bleeding related indicators:

2. Evidence of venous thrombosis, such as the presence of related symptoms or auxiliary tests indicating thrombosis; Or have a history of venous embolic disease.

3. Acute myocardial infarction or ischemic stroke occurred within 6 months before screening.

4. Presence of malignant tumors or history of malignant tumors.